Q&A: An­a­lyst-turned biotech ex­ec-turned an­a­lyst reads the biotech Q1 tea leaves

The coro­n­avirus pan­dem­ic is in full swing. Bio­phar­ma R&D and reg­u­la­to­ry time­lines have been dis­rupt­ed, sup­ply chains in­ter­rupt­ed and what the fu­ture holds is any­body’s guess. Now with the first quar­ter hav­ing come to a close, what can we ex­pect in earn­ings re­ports?

End­points News caught up with Yaron Wer­ber, man­ag­ing di­rec­tor and se­nior re­search an­a­lyst on Cowen’s biotech­nol­o­gy team for some crys­tal-ball gaz­ing.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER